OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.700
-0.190 (-10.05%)
At close: Feb 21, 2025, 4:00 PM
1.750
+0.050 (2.94%)
After-hours: Feb 21, 2025, 7:54 PM EST
OS Therapies Employees
As of December 31, 2022, OS Therapies had 4 total employees, including 3 full-time and 1 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,854,693
Market Cap
36.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
OSTX News
- 2 days ago - OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2 - Business Wire
- 7 days ago - Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer - Benzinga
- 8 days ago - OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing - Business Wire
- 18 days ago - OS Therapies Provides Corporate Update - Business Wire
- 5 weeks ago - OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy - Seeking Alpha
- 5 weeks ago - Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? - Benzinga
- 5 weeks ago - OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma - Business Wire
- 7 weeks ago - OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire